Year Authors/Creators Item Type Full Text

2022

Ethnic and socioeconomic disparities in initiation of second-line antidiabetic treatment for people with type 2 diabetes in England: A cross-sectional study. (2022) Bidulka, Patrick; Mathur, Rohini; Lugo-Palacios, David G; O'Neill, Stephen; Basu, Anirban; Silverwood, Richard J; Charlton, Paul; Briggs, Andrew; Smeeth, Liam; Adler, Amanda I; Douglas, Ian J; Khunti, Kamlesh; Grieve, Richard

The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease. (2022) Kaku, Kohei; Wanner, Christoph; Anker, Stefan D; Pocock, Stuart; Yasui, Atsutaka; Mattheus, Michaela; Lund, Søren S

2021

Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study. (2021) Patel, Krishna K; Gomes, Marilia B; Charbonnel, Bernard; Chen, Hungta; Cid-Ruzafa, Javier; Fenici, Peter; Hammar, Niklas; Ji, Linong; Kennedy, Kevin F; Khunti, Kamlesh; Kosiborod, Mikhail; Pocock, Stuart; Shestakova, Marina V; Shimomura, Iichiro; Surmont, Filip; Watada, Hirotaka; Arnold, Suzanne V

2020

Comparative effects of sulphonylureas, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors added to metformin monotherapy: a propensity-score matched cohort study in UK primary care. (2020) Wilkinson, Samantha; Williamson, Elizabeth; Pokrajac, Ana; Fogarty, Damian; Stirnadel-Farrant, Heide; Smeeth, Liam; Douglas, Ian J; Tomlinson, Laurie A

2019

Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme. (2019) Khunti, Kamlesh; Chen, Hungta; Cid-Ruzafa, Javier; Fenici, Peter; Gomes, Marilia B; Hammar, Niklas; Ji, Linong; Kosiborod, Mikhail; Pocock, Stuart; Shestakova, Marina V; Shimomura, Iichiro; Tang, Fengming; Watada, Hirotaka; Nicolucci, Antonio; DISCOVER investigators

Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme. (2019) Nicolucci, Antonio; Charbonnel, Bernard; Gomes, Marília B; Khunti, Kamlesh; Kosiborod, Mikhail; Shestakova, Marina V; Shimomura, Iichiro; Watada, Hirotaka; Chen, Hungta; Cid-Ruzafa, Javier; Fenici, Peter; Hammar, Niklas; Surmont, Filip; Tang, Fengming; Pocock, Stuart

2018

Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. (2018) Nauck, Michael A; Buse, John B; Mann, Johannes FE; Pocock, Stuart; Bosch-Traberg, Heidrun; Frimer-Larsen, Helle; Ye, Qing; Gray, Alastair; LEADER Publication Committee for the LEADER Trial Investigators

2017

Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany. (2017) Khunti, Kamlesh; Godec, Thomas R; Medina, Jesús; Garcia-Alvarez, Laura; Hiller, Josh; Gomes, Marilia B; Cid-Ruzafa, Javier; Charbonnel, Bernard; Fenici, Peter; Hammar, Niklas; Hashigami, Kiyoshi; Kosiborod, Mikhail; Nicolucci, Antonio; Shestakova, Marina V; Ji, Linong; Pocock, Stuart

Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review. (2017) Khunti, Kamlesh; Gomes, Marilia B; Pocock, Stuart; Shestakova, Marina V; Pintat, Stéphane; Fenici, Peter; Hammar, Niklas; Medina, Jesús

2016

Effectiveness and cost-effectiveness of interventions that cause weight loss and reduce the risk of cardiovascular disease. (2016) Zomer, Ella; Leach, Rachel; Trimmer, Christine; Lobstein, Tim; Morris, Stephen; James, William P; Finer, Nick

2015

Comparison of diabetes-associated secondary healthcare utilization between alternative oral antihyperglycaemic dual therapy combinations with metformin in patients with type 2 diabetes: an observational cohort study. (2015) Strongman, H; D'Oca, K; Langerman, H; Das, R

2013

Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. (2013) Goring, S; Hawkins, N; Wygant, G; Roudaut, M; Townsend, R; Wood, I; Barnett, AH

2011

Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. (2011) Caterson, ID; Finer, N; Coutinho, W; Van Gaal, LF; Maggioni, AP; Torp-Pedersen, C; Sharma, AM; Legler, UF; Shepherd, GM; Rode, RA; Perdok, RJ; Renz, CL; James, WPT; SCOUT Investigators

2007

Does insulin detemir have a role in reducing risk of insulin-associated weight gain? (2007) Hermansen, K; Davies, M

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. (2007) Hermansen, K; Kipnes, M; Luo, E; Fanurik, D; Khatami, H; Stein, P; Sitagliptin Study 035 Group

Gender and neurogenin3 influence the pathogenesis of ketosis-prone diabetes. (2007) Louet, J-F; Smith, SB; Gautier, J-F; Molokhia, M; Virally, M-L; Kevorkian, J-P; Guillausseau, P-J; Vexiau, P; Charpentier, G; German, MS; Vaisse, C; Urbanek, M; Mauvais-Jarvis, F